Parkinson's disease and dementia with Lewy bodies are currently defined by their clinical
features, with α-synuclein pathology as the gold standard to establish the definitive …

Growing evidence suggests an increasing significance for the extent of gastrointestinal tract
(GIT) dysfunction in Parkinson's disease (PD). Most patients suffer from GIT symptoms …

Background Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment
of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease …

Background Aggregated α-synuclein plays an important role in the pathogenesis of
Parkinson's disease. The monoclonal antibody prasinezumab, directed at aggregated α …

There are currently no effective biomarkers for diagnosing Parkinson's disease (PD) or
tracking its progression. Here, we developed an artificial intelligence (AI) model to detect PD …

Idiopathic REM sleep behaviour disorder (iRBD) is a powerful early sign of Parkinson's
disease, dementia with Lewy bodies, and multiple system atrophy. This provides an …

Background and Objectives Short-chain fatty acids (SCFAs) are gut microbial metabolites
that promote the disease process in a rodent model of Parkinson disease (PD), but fecal …

Gait impairments are among the most common and disabling symptoms of Parkinson's
disease. Nonetheless, gait is not routinely assessed quantitatively but is described in …

Disease staging is an important tool in both clinical research and medical practice because
it allows for an unequivocal allocation of individuals into groups of shared biomedical …

Parkinson's disease (PD) is a neurodegenerative disorder that produces both motor and non-
motor complications, degrading the quality of life of PD patients. Over the past two decades …